U.S. markets open in 3 hours 6 minutes
  • S&P Futures

    3,686.00
    +31.75 (+0.87%)
     
  • Dow Futures

    29,493.00
    +208.00 (+0.71%)
     
  • Nasdaq Futures

    11,320.00
    +91.75 (+0.82%)
     
  • Russell 2000 Futures

    1,700.90
    +18.80 (+1.12%)
     
  • Crude Oil

    81.51
    +0.28 (+0.34%)
     
  • Gold

    1,676.00
    +7.40 (+0.44%)
     
  • Silver

    19.07
    +0.35 (+1.89%)
     
  • EUR/USD

    0.9780
    -0.0039 (-0.40%)
     
  • 10-Yr Bond

    3.7470
    0.0000 (0.00%)
     
  • Vix

    31.02
    +0.84 (+2.78%)
     
  • GBP/USD

    1.1124
    +0.0000 (+0.00%)
     
  • USD/JPY

    144.4750
    +0.0320 (+0.02%)
     
  • BTC-USD

    19,530.35
    +85.95 (+0.44%)
     
  • CMC Crypto 200

    446.53
    +0.55 (+0.12%)
     
  • FTSE 100

    6,929.32
    +47.73 (+0.69%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know

·4 min read

Xeris Biopharma (XERS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Xeris Biopharma basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Xeris Biopharma imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate Revisions

Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for Xeris Biopharma

This company is expected to earn -$0.76 per share for the fiscal year ending December 2022, which represents a year-over-year change of 50.7%.

Analysts have been steadily raising their estimates for Xeris Biopharma. Over the past three months, the Zacks Consensus Estimate for the company has increased 5%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Xeris Biopharma to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Xeris Biopharma Holdings, Inc. (XERS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research